

Dimitrios Alexopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/101013/publications.pdf>

Version: 2024-02-01

45
papers

4,917
citations

471061

17
h-index

329751

37
g-index

46
all docs

46
docs citations

46
times ranked

6946
citing authors

#	ARTICLE	IF	CITATIONS
1	Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes. <i>Platelets</i> , 2022, 33, 390-397.	1.1	3
2	Persistent decline of hospitalizations for acute stroke and acute coronary syndrome during the second wave of the COVID-19 pandemic in Greece: collateral damage unaffected. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110295.	1.5	12
3	Vascular conditioning prevents adverse left ventricular remodelling after acute myocardial infarction: a randomised remote conditioning study. <i>Basic Research in Cardiology</i> , 2021, 116, 9.	2.5	24
4	Differential effects of heat-not-burn and conventional cigarettes on coronary flow, myocardial and vascular function. <i>Scientific Reports</i> , 2021, 11, 11808.	1.6	9
5	Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. <i>European Heart Journal</i> , 2021, 42, 4536-4549.	1.0	37
6	Temporal changes of noninvasive electrocardiographic risk factors for sudden cardiac death in post- ∞ myocardial infarction patients with preserved ejection fraction: Insights from the PRESERVE- ∞ EF study. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12701.	0.5	6
7	Editorial: The Ongoing Quest for Mono-Antiplatelet Therapy Post-PCI. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 790-791.	0.3	0
8	Tailoring Dual Antiplatelet Therapy for the Complex PCI Patient: Current Status and Perspectives. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 697-706.	1.3	7
9	Global Longitudinal Strain of the Systemic Ventricle Is Correlated with Plasma Galectin-3 and Predicts Major Cardiovascular Events in Adult Patients with Congenital Heart Disease. <i>Medicina (Lithuania)</i> , 2020, 56, 305.	0.8	6
10	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. <i>JAMA Network Open</i> , 2020, 3, e2013136.	2.8	344
11	\hat{I}^2 -Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 365-376.	1.0	11
12	Platelets from patients with myocardial infarction can activate T cells. <i>Haematologica</i> , 2020, 106, 288-290.	1.7	3
13	Left Main Coronary Interventions: A Practical Guide. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1596-1605.	0.3	2
14	Does Ticagrelor Improve Endothelial Function?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 11-17.	1.0	10
15	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	1.1	366
16	P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 717-727.	0.6	4
17	Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 139-148.	1.4	18
18	Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. <i>Clinical Research in Cardiology</i> , 2019, 108, 1093-1101.	1.5	41

#	ARTICLE	IF	CITATIONS
19	De-Escalation of Treatment With Oral P2Y ₁₂ Receptor Inhibitors: Current Status and Perspectives. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 304-314.	1.0	4
20	Early P2Y ₁₂ Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 852-863.	1.8	0
21	Absence of differential effect of ticagrelor versus prasugrel maintenance dose on endothelial function in patients with stable coronary artery disease. <i>Hellenic Journal of Cardiology</i> , 2018, 59, 338-343.	0.4	9
22	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246
23	Rationale and Design of the Effectiveness of Low-Dose maintenance dose of Ticagrelor early After myocardial infarction (ELECTRA) pilot study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 152-157.	1.4	16
24	Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 287-294.	1.3	31
25	Dyspnea in patients treated with P2Y ₁₂ receptor antagonists: insights from the GREEK AntiPlatelet (GRAPE) registry. <i>Platelets</i> , 2017, 28, 691-697.	1.1	9
26	Delayed onset of novel P2Y ₁₂ receptor antagonists action post fibrinolysis. <i>International Journal of Cardiology</i> , 2017, 234, 131.	0.8	0
27	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
28	Low-Dose Ticagrelor Versus Clopidogrel in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2091-2092.	1.2	6
29	P2Y ₁₂ Receptor Antagonists and Morphine. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	32
30	Long-Term P2Y ₁₂ -Receptor Antagonists in Post-Myocardial Infarction Patients. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1223-1232.	1.2	9
31	Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation. <i>Current Vascular Pharmacology</i> , 2016, 14, 487-491.	0.8	10
32	Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction. <i>Circulation</i> , 2015, 132, 1395-1403.	1.6	208
33	In-hospital switching of oral P2Y ₁₂ inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Prevalence, predictors and short-term outcome. <i>American Heart Journal</i> , 2014, 167, 68-76.e2.	1.2	70
34	Pleiotropic Effects of Platelet P2Y ₁₂ Receptor Inhibitors: Fact or Fiction?. <i>Current Pharmaceutical Design</i> , 2014, 20, 4597-4604.	0.9	4
35	Contraindications/Special Warnings and Precautions for Use of Contemporary Oral Antiplatelet Treatment in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2014, 78, 180-187.	0.7	18
36	Differential Effect of Ticagrelor Versus Prasugrel on Coronary Blood Flow Velocity in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 277-283.	1.4	59

#	ARTICLE	IF	CITATIONS
37	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	1.2	807
38	Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. <i>American Heart Journal</i> , 2011, 162, 733-739.	1.2	60
39	Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 403-410.	1.1	113
40	Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation. <i>US Cardiology Review</i> , 0, 15, .	0.5	0
41	Antithrombotic Therapy in Chronic Total Occlusion Interventions. <i>US Cardiology Review</i> , 0, 15, .	0.5	1
42	Left Main Disease and Bifurcation Percutaneous Coronary Intervention: Focus on Antithrombotic Therapy. <i>US Cardiology Review</i> , 0, 15, .	0.5	0
43	Platelet Function Testing and Genotyping for Tailoring Treatment in Complex PCI Patients. <i>US Cardiology Review</i> , 0, 15, .	0.5	1
44	Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment. <i>US Cardiology Review</i> , 0, 15, .	0.5	0
45	Use of Optical Coherence Tomography in MI with Non-obstructive Coronary Arteries. <i>Interventional Cardiology Review</i> , 0, 17, .	0.7	2